Pharma & Biotech ANNUAL REPORT
ND PHARMA & BIOTECH
Delivering value thru innovation. ND Pharma & Biotech brings to the market a unique mix of diversified research and innovation, leading healthcare business together in one growthfocused, successful company, owned and manged as a family based. We built our portfolios targeting and addressing customerÂ´s needs around the globe.
Important information for readers of this Annual Report. Use of terms In this Annual Report, unless the context otherwise requires, ‘ND Pharma & Biotech’, ‘the company’, ‘we’, ‘us’ and ‘our’ refer to ND Pharma & Biotech and its consolidated entities. This Annual Report is also available on our website. Statements of dates Except as otherwise stated, references to days and/or months in this Annual Report are references to days and/or months in 2013. Directors’ Report: The following sections make up the Directors’ Report, which has been prepared in accordance with the requirements of the Companies Act 2006, and may be encountered within the Directors´Report on preparation.
quirements; our ability to protect our intellectual property rights, and have suﬃcient rights to market our products and services, and the cost of doing so; problems with our manufacturing processes and our reliance on third parties; the risks of doing business internationally; failure to execute our growth initiatives; charges and other costs relating to our properties; fluctuations in our eﬀective tax rate; our ability to attract and retain qualified personnel; fluctuations in our operating results; the market, interest and credit risks associated with our portfolio of marketable shares; environmental risks; change of control provisions in our collaborations; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual report (c)4 2013 and in other reports we have. These statements are based on our current beliefs and expectations and speak only as of December, 5, 2013. We do not undertake any obligation to publicly update any forward-looking statements.
· Shareholder Information
NOTE REGARDING TRADEMARKS: PRESERFOOD®, ALKIOW®, GLAICE®, NOOPEPTIL®, KANGEN®, and ECOEFF® are registered trademarks of ND Pharma & Biotech Co. and/or its subsidiaries. Other marks as our branded ACARISINTM, STERILFOODTM, and INOFISHTM and many others conforming our branded product portfolio, are trademarks and/or fantasy names property of our company and/or its subsidiaries covered under IP. Despite this facts, it may be possible to change nomenclature to any of our products due to certian expected and/or unexpected reasons.
· Corporate Information
Any queries regarding this annual report?
Cautionary statement regarding forward-looking statements and Safe-harbor Policy: This annual report contains forward-looking statements, including statements about our 2013 goals, growth prospects and strategies, regulatory filings and agency actions, product launch plans, the anticipated development of and data readouts from programs in our clinical pipeline, and the expectation and anticipated benefits of our collaboration and research eﬀorts. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to diﬀer materially from those reflected in such statements, including our dependence on our principal products, uncertainty of success in executing our commercial launch ofnew products and agreements with certain partners and/or would be partners uncertainty of success in commercializing other product candidates; product competition; occurrence of adverse safety events with our products; changes in the availability of reimbursement for our products; adverse market and economic conditions; our dependence on collaborations and other third parties over which we may not always have full control; failure to comply with government regulation and legal and regulatory re-
Please made in writing to email@example.com, Ref: AR13.
· Strategy · Performance · Corporate Governance · Development Pipeline
(C) ND Pharma & Biotech 2013. 2
World in our hands
ND Pharma & Biotech
C.E.O. ND Pharma & Biotech 400 % SUSTAINED GROWTH IN NET SALES
Dear friend, customer, investor or prospective:
Every other day our universe is expanding. We are growing
DEBT WITH CREDITORS /BANKERS
continuously, in an ever expanding circle, improving for you, our brands, our products, our research, with the same drive, motivation and illusion that let us to reach this point of success and implementation of our philosophy of service and clean behaviour with our customers. The ND Pharma & Biotech family is growing
STATEMENT OF CAPITAL
also in diﬀerent aspects and directions, so this growing were nearby impossible to
be reflected just on a website, flyer or catalogue. This is why we create diﬀerent
ESTIMATED R+D ACTUAL PROTFOLIO VALUE
thematic websites, because we want to share with what we are and what we´re doing in a more informational, illustrative and commercial manner, showing and sharing new and more advanced points of interest for you, thru the open
exposition of our corporate websites and pages.
ESTIMATED AVERAGE GROWTH BY
Our science connects us to people and communities everywhere. Behind ND
SECTORS (NEXT FISCAL YEAR
Pharma & Biotech science are our cooperators, scientists, associated centers,
ND Pharma & Biotech
laboratories, partners, researcher teams, suppliers, employees and a number of
anonymous people helping us to reach our objectives, who go to work every day 4
with the goal of strengthening the connections that allow us to
research, development and innovation, to make life better, as it´s
develop and deliver products, from API´s to branded, from animal
care to human medicines to all those that are in need. We rely on our Board of Directors and Scientific Advisers to provide oversight and guidance as we work to achieve our vision.This is why we call to all of them Consultants. Like many of our industry peers, we continue to navigate the obstacles posed by the external global economic environment. In the face of those challenges, we made tremendous progress in 2013 and we look ahead to exciting milestones that will drive our business in 2014 and well beyond. We expect an increase of capital from our actual numbers to a 30% more in the next two yeas thanks to our portfolio estimated value that is increasisng substantially at every step. If allowed, we will issue a number of shares at the end of 2015.
On behalf of the ND Pharma & Biotech family let me invite you to explore our world, the ND World, a complete universe of science, research and innovation designed to serve you, and of course, to make life better, as our mission prays. So please, feel free to browse and surf over our diﬀerent sites, hosting and microsites, as well as within this pages and let us to be part of our life also. You deserve and we worth it. If you may have any query or question arising, please feel free of contacting us, myself and the dedicated team of professionals thar every day, with their eﬀorts are making of this company, the best ever place to work. Sincerely Yours.
Over the long term, and centered in the pharma-business we believe the most valuable way to sustain and build value is to continue focusing on our science – the science that drives us to identify novel therapies in areas of unmet medical need, best characterize the profile of our existing products and communicate the value our products and future medications will have to society.
Jess P. Harford, CEO ND Pharma & Biotech Co. Ltd.
As we move ahead together, I thank you for your interest in ND Pharma & Biotech and your shared commitment to excellence in
products suitable for health protection
product or service provided. Most
and wellnes promotion for people
products are marketed primarily through
everywhere, decreasing dependence on
the company's sales force, although in
toxic chemicals and protecting life and
some regions, more emphasis is placed
t h e e n v i ro n m e n t . O u r s y s t e m o f
on sales through distributors. The
collaborative and cooperative work let us
company utilizes numerous suppliers as
to count a total worldwide employment
well as internal sources to supply a wide
ND Pharma & Biotech Company Limited
at December 31, of 53 direct and 300
range of raw materials, energy, supplies,
brings world-class science and products
(mostly indirect) people. The company
services and equipment. To ensure
to the global marketplace in the form of
has operations in a number of countries
availability, the company maintains
innovative products, materials and
worldwide and about 60 percent of
multiple sources for many raw materials.
services. The company believes that by
consolidated net sales are made to
Large volume purchases are generally
collaborating with customers,
customers within the EU actually.
procured under competitively priced
The Company ND Pharma & Biotech Co. was founded in 2009 and was incorporated in England and Wales in 2012 as a company limited by shares with a total shares amount of 210.000.100 of 1 GBP each one.
governments, non-gov-organizations and thought leaders it can help find solutions to such global challenges as providing solutions for certain medical and health conditions society has to deal now, improvement of pharmaceuticals, biochemicals, APIÂ´s, intermediates, reagents, and rare chemicals, trading products, fine and non poisonous ingredients, and many more products, in order to let manufacturers and industry sectors to ellaborate healthy foods, beverages, medicines, and many other
Subsidiaries and aďŹƒliates of ND Pharma
& Biotech Co., conduct manufacturing, production or selling activities and some are distributors of products manufactured by the company. As a science and technology based company, ND Pharma & Biotech competes on a variety of factors such as product quality and performance or specifications, continuity of supply, price, customer service and breadth of product line, depending on the characteristics of the particular market involved and the
Our Business ND Pharma & Biotech Company Limited. (ND Pharma, the Company, we or us), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs and operate and conduct businesses 6
many other fields and sectors, most of
industry processes and fields from
them related to human health as food,
health to nutrition or crop protection.
nutrition, biosciences, neurosciences, etc. In the Bio-Pharmaceutical sector, as example, and with each new discovery and experimental drug candidate, we seek to improve the care of patients suďŹ€ering from life-threatening diseases around the world. Headquartered in the U.K., we have
Business Segments The company's reportable segments are R+D+i, Communications, Industrial Biosciences, Food, Nutrition & Health, Performance Chemicals, Performance Materials, Safety & Protection, BioPharmaceuticals, Pharmacy, Health & Medicine, Public Health, Consumer Brands, and Innovation Management.
operations in North and Latin America,
The company includes certain embryonic
Europe and Asia. We continue to add
businesses not included in the reportable
to our existing portfolio of products
segments, such as pre-commercial
through our internal discovery and
programs, and nonaligned businesses as
clinical development programs and
Stem Cell Technology, and some start-up
through a product acquisition and in-
As the world's population grows and the
During our short existence we have launched a number of products, technologies and brands that are re v o l u t i o n i z i n g c e r t a i n s p e c i fi c
middle class expands, the need for crops for animal feed, food, biofuels and industrial uses continues to increase. The business competes with other fields and sectors as it usually happens within biotechnology companies.
Backlog In general, the company does not manufacture its products against a backlog of orders and does not consider backlog to be a significant indicator of the level of future sales activity. Production and inventory levels are based on the level of incoming orders as well as projections of future demand. Therefore, the company believes that backlog information is not material to understanding its overall business and should not be considered a reliable indicator of the company's ability to achieve any particular level of revenue or financial performance. Intellectual Property ND Pharma & Biotech believes that its intellectual property estate provides it with an important competitive advantage. It has an established global network of attorneys, agents and experts as well as branding, advertising and licensing professionals, to procure, 7
maintain, protect, enhance and gain
of total portfolio is situated around the
will continue to be important to ND
value from this estate.
750 Mâ‚Ź, at the end of December 2013.
Pharma & Biotech and its competitors.
The company has access to a large
Trade secrets are an important element
patent portfolio, both owned and
of the company's intellectual property.
licensed. These definite-lived patents
Many of the processes used to make ND
cover many products, processes and
Pharma & Biotech products are kept as
trade secrets which, from time to time,
These patents protect many aspects of the company's significant research programs and the goods and services it sells. The actual protection aďŹ€orded by these patents varies from country to country and depends upon the scope of coverage of each individual patent as well as the availability of legal remedies in each country. ND Pharma & Biotech Co, has accounted practically the total amount of its statement of capital on the estimated value of IP rights and other applicable rights under its patents and licenses, as well as the products made
may be licensed to third parties. ND Pharma & Biotech vigilantly protects all of its intellectual property including its trade secrets. When the Company discovers that its trade secrets have been unlawfully taken, it reports the matter to governmental authorities for investigation and potential criminal action, as appropriate. In addition, the company takes measures to mitigate any potential impact, which may include civil actions seeking redress, restitution and/ or damages based on loss to the company and/or unjust enrichment.
The environment in which Company competes is characterized by the use among competitors of intellectual property rights, including patent lawsuits, to gain advantage in commercial markets. In support of its business, ND Pharma & Biotech Co. continues to build a large collection of intellectual property rights related to biotechnology and other fields and sectors where the company operates and to license technology from others, including competitors. ND Pharma & Biotech Co., endeavors to obtain such licenses on commercially reasonable terms. Research and Development The company conducts research at either dedicated research facilities or manufacturing plants. There are eleven
and sold under them, that are important
Ownership of and access to intellectual
major research locations in the U.S. &
to the company as a whole, and to
property rights, particularly those relating
Canada, The United Kingdom, Spain and
varying degrees, important to each
to biotechnology and innovations in
Asia (Japan). Reflecting the company's
reportable segment. The estimated value
food, nutrition, ingredientÂ´s health, etc. ,
global interests, research locations are 8
located in the Asia Pacific region, in
products and processes. Each segment
not dependent upon the outcome of any
Europe, Middle East and Africa (EMEA)
of the company funds research and
single research program.
region and one major location is located
development activities that support its
in Latin America.
business mission. The company is
Research is the main activity of our Company, that is purported thru ND Innovation (a wholly owned subsidiary of ND Pharma & Biotech Co.)
expanding its oﬀerings addressing safety, environment, energy and climate challenges in the global marketplace by
The senior research management is leaded by the Chief Scientiic Oﬃcer, that is also a member of the Board. Competition
developing and commercializing re n e w a b l e , b i o - b a s e d m a t e r i a l s ;
Our marketed products target a number
The company has a number of unique
advanced biofuels; energy-eﬃcient
of areas. There are many commercially
trademarks for its products and services
technologies; enhanced safety and
available products from ND Pharma &
and holds also a number of registrations
protection products; and alternative
Biotech Co,, as well as many brands and
for these trademarks worldwide.
energy products and technologies as
third party´s products improved thru our
well as real innovations in about all
innovations or incorporating such. Many
Ownership rights in trademarks do not
sectors and fields where the company
companies and institutions are making
expire if the trademarks are continued in
isoperating actually. The goals are tied
substantial investments in developing
use and properly protected. The
directly to business growth, including
additional products to re-sahpe,
company has many trademarks that
increasing food production, increasing
i m p ro v e , t o t a l l y c h a n g e a n d re -
have significant recognition at the
renewable sources for energy and raw
positioning their own brands and
consumer retail level and/or business to
materials, and providing greater safety
products thamks to our developments.
and protection for people and the
Our products compete with other
environment. All research and
available products based primarily on
development activities are administered
eﬃcacy; safety; tolerability; acceptance
by senior research and development
by consumers, industry, producers,
management to ensure consistency with
processors, and many others; ease of
the business and corporate strategy so
patient compliance; patent protection;
therefore the future of the company is
ease of use; price;
The objectives of the company's research and development programs are to create new technologies, processes and business opportunities in relevant fields, as well as to improve existing
distribution and 9
We developed an strategyc
that govern the manufacture, sale,
patent that prevents us from using
competition based on some of our
distribution and/or marketing of our
technology we create.
unrivalled products and brands.
products in various territories worldwide,
we entered in some quite interesting commercial collaborations with those
As part of our business strategy, we
that are most significant to us from a
establish collaborations with other
financial statement perspective and
companies, universities and medical
where significant ongoing collaboration
research institutions to assist in the
clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from
Some of our existing partners are listed within our websites and commercial micro-sites that can be accessed thru ndpharmabiotech.com.
As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. We also rely on trade secrets, internal know-how, technological innovations and agreements with third parties to develop, maintain and protect our
Patent Protection and Certain
competitive position. Our ability to be
Challenges relative to medicines,
competitive will depend on the success
health products, and related
of this strategy.
Patents covering the active
other companies, universities and
Patents and other proprietary rights are
pharmaceutical ingredients of some of
medical research institutions,
very important to our business. If we
our developments are held by third
technological centers and other
have a properly drafted and enforceable
parties. We acquired exclusive rights to
patent, it can be more diďŹƒcult for our
these patents in the agreements we have
competitors to use our technology to
with these parties.
Commercial Collaborations Although we currently have a number of collaborations with corporate partners
create competitive products and more diďŹƒcult for our competitors to obtain a
Patents do not cover the total developments weÂ´ve made and those we 10
are discovering. When this happens we
It is also very important that we do not
However, the existence of issued patents
cover formulations of this compounds
infringe the valid patents or proprietary
does not guarantee our right to practice
and also protect such formulations
rights of others and that we do not
the patented technology and/or
through trade secrets.
violate the agreements that grant
commercialize the patented product.
We may obtain patents for certain
proprietary rights to us.
Third parties may have or obtain rights to
products many years before marketing
If we do infringe valid patents or violate
patents which they may claim could be
approval is obtained for those products.
these agreements, we may be prevented
used to prevent or attempt to prevent us
from commercializing products or from
from commercializing the patented
using the processes covered by those
product candidates obtained from the
patents or agreements, or may be
Because patents have a limited life, which may begin to run prior to the commercial sale of the related product, the commercial value of the patent may be limited. However, we may be able to apply for patent term extensions and
required to obtain a license from third parties to allow us to use their technology.
We are aware of patents and patent applications owned by other parties that might be alleged to cover the use of
other many forms of IP rights protection
We may be unable to obtain alternative
certain products that were developed by
a s s u p p l e m e n t a r y c e r t i fi c a t e s o r
technologies or any required license on
us, somtimes prior to Company
supplementary protection certificates on
reasonable terms or at all.
formation and regularization, protection
many of our products that have been granted in the United States and in a number of European countries, compensating in part for delays in obtaining marketing approvals. Similar patent term extensions may be available for other products that we are developing, but we cannot be certain we will obtain them in some countries.
If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. We own patents that claim for certain molecules as a chemical entity (CEÂ´s) and its metabolites.
and/or reconciliation with our own developments, molecules, chemical entities and discoveries. If these other parties are successful in obtaining valid and enforceable patents, and establishing our infringement of those patents, we could be prevented from selling some of those molecules unless we were able to obtain a license 11
under such patents. If any license is
in interference/derivation proceedings or
needed it may not be available on
litigation to determine the right to a
commercially reasonable terms or at all.
patent. Litigation and interference/
ND Pharma & Biotech (as successor to PharmaCot Health Technologies) is a party to a collaboration agreement with some existing companies as IBT Chicago or the most recent OLT, Denver. B e c a u s e p a t e n t a p p l i c a t i o n s a re confidential for a period of time until a patent is issued, we may not know if our c o m p e t i t o r s h a v e fi l e d p a t e n t applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the
derivation proceedings are unpredictable and expensive, such that, even if we are ultimately successful, our results of operations may be adversely aďŹ€ected by such events. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection.
technology that is the subject of our
Future litigation or re-examination
proceedings regarding the enforcement
Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our products. In addition, if competitors file patent applications covering our technology, we may have to participate
Manufacturing and Raw Materials Our manufacturing strategy is to contract with third parties to manufacture the majority of our active pharmaceutical ingredients and solid dose products. We also rely on our corporate partners to manufacture certain of our products. These include food & nutrition formulas, compounds, etc. Additionally, we own or lease manufacturing facilities where we manufacture certain products and active pharmaceutical ingredients for clinical and commercial uses as well as a pilot plant where we manufacture the vast majority of our pre-packed/ready-to-go products and samples under higher standards.
or validity of our existing patents or any
Manufacturing of our Products
future patents could invalidate our
We contract with third parties to
patents or substantially reduce their protection. From time to time, certain individuals or entities may challenge our patents, what constitutes also a risk factor to our company.
manufacture certain products for clinical and commercial purposes including some of our trademarks from PreserFood TM to Noopeptil TM.
We use multiple third-party contract
and to manufacture suﬃcient quantities
To the extent these risks materialize and
manufacturers to manufacture some of
of any product that is approved for
aﬀect their performance obligations to
our API´s. We rely on a single third-party
commercial sale. If we are unable to
us, our financial results may be adversely
manufacturer to manufacture some of
develop manufacturing capabilities
our StarBranded® products and some
internally or contract for large scale
others under the “SOL” TERMINATION
manufacturing with third parties on
AS SUCRASOL®, ASPARSOL®, etc.
acceptable terms for our future products,
We are the exclusive manufacturer of the active pharmaceutical ingredients that we sell under our SpeciBrands® within a certified premises throughout a subsidiary company that is fully operated by ND Pharma & Biotech.
our ability to conduct large scale clinical trials and meet customer demand for commercial products will be adversely aﬀected. Third-party Manufacturers
We believe the technology we use to manufacture our products is proprietary. For products manufactured by our thirdparty contract manufacturers, we have disclosed all necessary aspects of this technology to enable them to manufacture the products for us. We have agreements with these third-
Our third-party manufacturers and our
party manufacturers that are intended to
We also rely on third-party contract
corporate partners are independent
restrict these manufacturers from using
manufacturers to tablet or capsulate
entities who are subject to their own
or revealing this technology, but we
unique operational and financial risks
cannot be certain that these third-party
which are out of our control.
manufacturers will comply with these
We also have manufacturing agreements with many of our corporate partners. For our future products, we continue to develop additional manufacturing capabilities and establish additional third-party suppliers to manufacture suﬃcient quantities of our product candidates to undertake clinical trials
I f w e o r a n y o f o u r t h i rd - p a r t y manufacturers or our corporate partners fail to perform as required, this could impair our ability to deliver our products on a timely basis or receive royalties or
restrictions. In addition, these third-party manufacturers could develop their own technology related to the work they perform for us that we may need to manufacture our products.
cause delays in our clinical trials and
We could be required to enter into
applications for regulatory approval.
additional agreements with these thirdparty manufacturers if we want to use 13
that technology ourselves or allow
etc. The company has top compliance
Our worldwide product sales do not
another manufacturer to use that
standadrs and such exigences apply
re fl e c t a n y s i g n i fi c a n t d e g re e o f
technology. The third-party manufacturer
also for other operators and entities
could refuse to allow us to use their
working for us.
technology or could demand terms to use their technology that are not acceptable to us. Regulation of Manufacturing Process The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.
However, our royalty revenues, which
Our manufacturing operations are
represented approximately 3% of our
subject to routine inspections by
total revenues in 2013 are aﬀected by
re g u l a t o r y a g e n c i e s t h a t w e a re
seasonality. For the most part, we
conformed and became resolved without
operate in markets characterized by
short lead times and the absence of
Access to Supplies and Materials
significant backlogs. We do not believe that backlog information is material to
We need access to certain supplies and
our business as a whole, as stated
products to manufacture our products. If
previously within this document.
delivery of material from our suppliers
We, our third-party manufacturers and
were interrupted for any reason or if we
our corporate partners are subject to
are unable to purchase suﬃcient
Our operations and activities are subject
current Good Manufacturing Practices,
quantities of raw materials used to
to extensive regulation by numerous
w h i c h a re e x t e n s i v e re g u l a t i o n s
manufacture our products, we may be
government authorities in the United
governing manufacturing processes,
unable to ship certain of our products for
States and other countries. In the United
stability testing, record keeping and
commercial supply or to supply our
States, drugs are subject to rigorous FDA
quality standards as defined by the FDA
product candidates in development for
regulation. The Federal Food, Drug and
and the EMA. and other regulatory
Cosmetic Act and other federal and state
bodies in diﬀerent parts of the World. Similar regulations are in eﬀect in other fields and sectors as Food & Nutrition,
Seasonal Operations and Backlog
statutes and regulations govern the testing, manufacture, safety, eﬃcacy, labeling, storage, record keeping, approval, advertising and promotion of 14
our products. As a result of these
involve three separate phases that often
regulations, product development and
overlap, can take many years and are
appears to be eﬀective and safe in
product approval processes are very
very expensive. These three phases,
Phase 2 clinical trials, Phase 3 clinical
expensive and time consuming.
which are subject to considerable
trials are commenced to confirm those
regulation, are as follows:
results. Phase 3 clinical trials are
The FDA must approve a drug before it can be sold in the United States. The
general process for this approval is as
is given to a small number of healthy
human control subjects or patients
Phase 1. The drug candidate
suﬀering from the indicated disease, to t e s t f o r s a f e t y, d o s e t o l e r a n c e ,
Before we can test a drug candidate in
humans, we must study the drug in
distribution and excretion.
Phase 3. If a drug candidate
conducted over a longer term, involve a significantly larger population, are conducted at numerous sites in diﬀerent geographic regions and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug candidate. It is not uncommon for a drug candidate that
laboratory experiments and in animals to
appears promising in Phase 2 clinical
generate data to support the drug
trials to fail in the more rigorous and
candidate's potential benefits and safety.
We submit this data to the FDA in an
is given to a limited patient population to
investigational new drug (IND)
determine the eﬀect of the drug
application seeking its approval to test
candidate in treating the disease, the
the compound in humans.
best dose of the drug candidate, and the
Clinical Trials If the FDA accepts the investigational new drug application, the drug candidate can then be studied in human clinical trials to determine if the drug candidate
Phase 2. The drug candidate
extensive Phase 3 clinical trials.
possible side eﬀects and safety risks of the drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 1 clinical trials to fail in the more rigorous Phase 2 clinical trials.
is safe and eﬀective. These clinical trials 15
ND Pharma & Biotech
The World in our hands ND Pharma & Biotech is growing every year over any expectation
business trading and economy. Other locations worldwide are
assumed beforehand. We are serving a number of industries,
maintained operatively to serve our customers (existing and
from pharmaceutical to other health and nutrition, food and
prospective) through a net of alliances and agreements with a
beverages, animal nutrition and care, agriculture, as well as other
number of well-reputed and solvent partners and distributors.
industrial sector where we operate and entered with great success. Every day our innovations are being part of the everyday life, improving the quality of products that our clients are oﬀering to the final consumer. Our branded products, active principles, innovative formulas and multi-purpose solutions are used to provide health and wellness solutions to a number of problems and former unresolved questions within diﬀerent industry sectors from pharmaceutical preparations to alcoholic drinks and
Our Research Centre is also growing and expanding, as it is consistent with our policies of fast-service and high profile innovation. We´ve divided worldwide operations into five main blocks; The E.M.E.A. (aka Europe, Mid-East & Africa) which represents our main field of operations; The Americas (North, South and Central America including Caribbean), Asia-Pacific and EurAsia (russia and surrounding countries).
beverages industries that are willing to perform better, entering in
We´ve discovered that an increasing large number of countries
a new generation of spirits making them extremely enjoyable
are demanding our expertise, products and services. We are well
social and at the same time, decreasing and limiting the negative
prepared to serve them and willing to do so.
impact such drinks may have on human health. We are headquartered in England, United Kingdom, with Registered Oﬃce in Surrey. We´ve moved our administrative headquarters to Central London, the vibrant heart of world 17
ND Pharma & Biotech
President Letter The ending 2013 was an exceptional year to ND Pharma & Biotech. The company reached and unexpected growth in terms of net sales and revenues. Our products are being distributed all over the world. We are opening several sectors with
TO OUR FELLOW: EMPLOYEES, SUPPLIERS, DISTRIBUTORS, AGENTS, SHAREHOLDERS,
CUSTOMERS AND FRIENDS.
cutting-edge innovation and developments, so our products and solutions are reaching more and more companies, and therefore more and more people. Our company moved so fast from a biotech start-up to a multinational biopharmaceutical company with lines of development far from imagination and a solid advancing commercial, marketing and sales operative network. The organization is inspired by a number of mottos, all implied in the structured vision and mission that founders and oďŹƒcials traced from the very beginning. All this is not and never would be possible without the help and dedication of all people around our company, from shareholders that took the risk of financing it, to employees, suppliers, agents, distributors, customers and any other one involved with us, in a loop of friends, as we agree to call to all of them, because we consider to every and one, above any other consideration, a FRIEND. This friendly environment is the trademark of our company. We want to be loyal to such inspirational value that moves the world alongside other important values to an industry as our. From the universal love, tender, compassion, understanding, care, to the more dedicated people that make such words something more than simple words, transforming each one into something with great significance 19
throughout their acts and behaviour, our company is willing to
that led us to open 3 new manufacturing centres under
give all those people, enough tools to get some parts of all that
contracting, two of them at two diﬀerent European member states
done. This is why we invest some of our eﬀorts to advance some
(Spain and Poland) and the third of them in the United States.
of the most complex issues existing within human health, nutrition, food, animal care and the eﬀort we made to alleviate the burden of all the complications imply from an over-chemical world, and the misuse of such chemical machinery to reach a better society, reducing the exposure to certain chemicals, the intake thru processed foods and aliments, and the problems derived from such practices, most of the time largely ignored by regulators, industry operators and consumers. Our performance is commencing with the number of achievements our company reached despite the numerous macroeconomic headwinds, including country-specific economic challenges, currency devaluations and higher raw material prices, that are evolving to a high escalade of rising that seems not to be an end.
We continue to develop our business network with a strong disembarking in certain countries, mainly in Northern Europe an Russian satellite countries, and expanding in a non-stop growing strategy all across Latin-America, Brazil, Mexico and the U.S, in a world-class level performance with hundreds of targeting companies reaching up our products and improving their own with the help of our company. As much as we enjoy sharing our success from the ending year, I am also equally enthusiastic about our prospects for the near future. Our divisional societies, our subsidiaries and all the branches of this company group is performing quite well, so this is why we are attracting other companies to act and serve to us as partners in business development and success sharing. We are establishing strong relationships with third parties and
A few other accomplishments stand out as particularly
companies both within the industrial sector as well as into the
meaningful to me. First, as is evident from the evolution of our
great distribution, with some multi-billion dollar companies on our
reports even, we are developing ourselves into a brighter and
partnership plans, so it´s expected a rush of agreements to
promissory future ahead, reflected in a better and well-optimized
launch to the markets, a number of developments that, to be
business model and product portfolio. The reception and
honest, are far from our capacity of market, expressed this in
response from our people, employees, customers, suppliers and
terms of time-planning and marketing organization protocols.
investors has been quite positive. We are open a world of possibilities thanks to new agreements and project development
In closing, I want to recognize all the eﬀorts made by our oﬃcials and executive management team, supported by our dedicated 20
leaders within the diďŹ€erent areas. All of them are serving the company making great contributions. This is why we are expressing publicly here our grateful thanks. The last words are for our outstanding employees and executives. We never could be a great company without them and their behaviour that is more than a rock-solid foundation. Thanks to the board of directors for their continuing role in guiding and supporting the management of the company. And finally, thanks to our FRIENDS, all and one conforming in one way or another, part of this little great family that ND Pharma & Biotech is now.
David M. Hwang President of the Board of Directors
ND Pharma & Biotech
Company Today AREAS
ND Pharma & Biotech is a family owned company. Founded in 2008, as a divisional society of a
1. Research+ Development
large group of businesses related to the primary sector. Initially, the founder´s club attracted by the
blend of experiences and the outstanding professional trajectories gained from the average 25 years within the sector, became forced to move forward within the independence of the company from its
parent society. During the period of 2009- 2010 company was ready to market as independent and
4. Food & Nutrition
launched several world-wide successful products and developments. 2011 was a consolidation year
5. Agri-Business 6. Industrial
with entering in the market of new lines and brands of own developments mainly with the rising of the Food & Nutrition division. 2012, marked an impressive record of unparalleled achievements, and company established a business projection overwhelming any prevision or capacity. ND Pharma & Biotech operates within the national and international markets of raw materials, elaborated and specialty products, growing every other day it´s commercial structure and business operations , without loosing the innovative talent and capacities owned and maintained, principal asset of the company. The company has developed diﬀerent lines of business from Pharmaceutical and Healthcare to AgriBusiness, and each division is operating under the same heads and managers. Within this website the Product Portfolio can be explored to conforma a more accurate opinion about the company and the work we developed from the very inside, thanks to our in-house team of experienced scientists, researchers and academicians, as well as our Reference Laboratories and Associated Research Centers Worldwide, most of them from First Line Institutions as Universities, Clinical Centers, and other well reputed established programs of R+D+i around the globe. 23
ND Pharma & Biotech
Research+Development+Innovation We vigorously invest in research, development and innovation to
considered best in class for the industry, and we have followed
discover and develop new products and eventually, new
our products into new specialty areas.
treatments that meet the needs of specialty doctors and their patients.
Our R&D+i programs today are focused in many areas ranging from diabetes and nutrition to surgical innovations. Currently, we
Our company try to develop world-class research + development
are investigating a rich arsenal of potential new treatments for
+ innovation (R&D) programs that embodies our eďŹ€orts to bring
chronic migraine, debilitating neurological conditions, eye
the best of science to medicine and therefore to life, including
disease, and stem cell transplantation, among other conditions
some new developments within the nutrition science, food, feed
and fields. Significant progress in these areas is expected to be
and certain industrial sectors.
made over the next decade - advances in which we look forward
Scientists and researchers work closely with specialists within
playing a prominent role.
their respective areas, to transform novel compounds into new
Since founding, our company retains the ability to listen and to
therapeutics and products that help improve quality of life. This
learn - from our customers, and from each other - has been a
philosophy is consistent with our motto; Making Life Better.
cornerstone of our success. ND Pharma & BiotechÂ´s R&D+i
Our commitment to R&D has been evident since our inception, when we began pioneering new treatments to help preserve certain organic and body functions including neurological
culture reflects this, providing an open forum for our and other scientists to share ideas, collaborate on projects, and gain access to the latest research.
functions as memory and cognoscitive abilities. Since then, our
Access to world-class technology combined with intellectual
investment in R&D+i has progressively increased to a level that is
stimulation results in a dynamic environment where scientists are
excited about the work they do and committed to pushing the boundaries of what is possible. Our R&D+i organization is structured into integrated teams that focus on discovery for diďŹ€erent targets. This unique architecture aďŹ€ords many benefits. Scientists normally confined to specific
For every new treatment/product that comes to market, hundreds of important discoveries are made along the way that contribute to science, medicine, health and technology. For these contributions and many others, ND Pharma & Biotech provides several opportunities for our scientists to be recognized and rewarded for excellent work in their respective fields and broadly.
tracks have the opportunity to be involved in the full life-cycle of
Research at our company is ongoing, and with some of the best
development, from early-stage exploration to human testing, for a
talent in the health care industry, our scientists regularly publish
much broader perspective. Additionally, meticulous research is
key findings in peer-reviewed medical journals and other scientific
streamlined with highly eďŹƒcient project and information
publications both indexed or not. Company also attends key medi-
management, which can save years and millions of dollars from
cal and industry meetings throughout the year, where our scien-
the overall cost of drug development.
tists present their published findings and research in front of their peers.
Most of our discovery and development programs are initiated internally, which sets us apart from many other health care
We are grateful to those members on and related to any of our
companies. Simultaneously, we explore new market opportunities
teams who have demonstrated their commitment to science, te-
and search for partnerships to develop superior technologies that
chnology, healthcare and medicine. Their commitment, intellect,
are complementary to our own business model.
and innovative thinking have the power to advance clinical discove-
In short, at our company, there will be only one way in which we view the purpose of science and innovation - to identify those needs in health care and certain industrial sectors that are unsolved and commit to finding solutions through a meaningful R&D+i investment that fuels future growth. This is our unwavering commitment. Our Commitment with/for Excellence in Research & Development.
ries and product development and improve the way we and our beloved ones are living. Our scientists, team leader and project managers are selected and distinguished members of different well-known, well-reputed scientific, medical and research organizations, professional bodies and institutions, maintaining membership and good standing with all relevant societies and up-to-date information, tools and means.
ND Pharma & Biotech
Inventing Future Excellence in Research For every new treatment that comes to market, hundreds of important discoveries are made along the way that contribute to science, medicine, and technology. For these contributions and many others, ND Pharma & Biotech provides several opportunities for our scientists to be recognized and rewarded for excellent work. Research at ND Pharma & Biotech is ongoing, and with some of the best talent in the health care industry, our scientists and research cooperators regularly publish key findings in peer-reviewed medical and scientific journals. We also attend key medical and industry meetings throughout the year, where our scientists present their published findings and research in front of their peers. We are grateful to those members on the ND Science team who have demonstrated their commitment to science, technology, and medicine. Their commitment, intellect, and innovative thinking have the power to advance clinical discoveries and improve the way we live.
Corporate Research Agreements and collaborations
coveries appear certain forms of plant-derived new molecules for the treatment of most aggressive conditions.
While most of our discovery and development programs are developed internally - making ND Pharma & Bitoech quite unique in the
Agreements with major industry labs and research organiza-
industry - we are continuously looking for partnerships and supe-
tions to develop solutions for food and nutrition industry in or-
rior technology that complement our business model. Some of our
der to achieve one of our motivational goals of removing to-
current collaborations include:
xic chemicals from food within the industry.
Exclusive licensing agreements with multi-purpose Research
ND PHARMA & BIOTECH is constantly seeking for partnerships
Centers and Universities Worldwide, including some of the
and associations in everyone of the fields that we developed and
most prominent in the fields.
where we conduct business. These partnerships and associations include academic institutions, research centers, other corporations
A multi-year alliance with Mayfield Clinic and major providers
of Regenerative Research and Treatment in the Stem Cells sector.
Partnering is a key component of our business strategy, as we consider every possibility to develop and partner successful pro-
Multiple lines of research opened within different private insti-
grams to pharmaceutical, biotechnology and medical device pro-
tutions worldwide where ND Pharma & Biotech participates
ducts, services, components and companies.
within different collaborative ways.
We welcome enquiries from other companies wishing to discuss any partnering opportunity with us.
Our new molecules laboratory develops and investigate within new molecule´s latest developments to give industry
In-Licensing is another source of business for us. We welcome
and professionals different levels of response and tools to
contacts from academic institutions, inventors, researchers and
fight against certain conditions and unmet medical and
other operatori within the industry from biotech, pharma, or other
health illnesses from neurology to orthopedics, eye care to
related fields. Our prime filter criteria is based on a three step con-
vascular disorders o addictions medicine. Between those dis-
sideration initial process: •
have strong intellectual property positions; 29
address significant unmet medical, health, food, nutrition, or
We offer distinctive solutions to a number of unmet clinical condi-
analogue needs, and
tions, diseases and pathologies.
have the potential to enter into development within 12 to 18 months after acquisition or licensing.
Working with corporate partners.
Business development and clients. ND PHARMA & BIOTECH entered into some important and interesting corporate deals with major companies worldwide. So some
ND PHARMA & BIOTECH focuses in developing pioneering and
of the "multi-billion dollar" corporations are now within our client´s
novel products, drugs, and molecules in specialist areas, from
list. Specifically within the food and nutrition industry we develo-
food to pharma and therapy where there is a distinct lack of exis-
ped product innovation and license deals with the major producers
ting solutions, with emphasis in personalized medicine and novel
of drinks, sodas, sport beverages and related industry sectors in
therapies in the field of Regenerative Medicine, Stem Cell Advan-
the field, helping them to improve the quality, health and nutrition
cement and other like nutrition.
properties of their own products, both existing and other to appear.
Since our foundation, our research strategy has been to work clo-
Other huge market corporations we work for include desert and
sely to different "first line" institutions and operational centers that
ice-cream industry, infant nutrition labs and manufacturers, and lar-
conduct investigation for us, under guidance and supervision of
ge corporation of general foods.
our clinical & scientific director´s team. These institutional coopera-
ND PHARMA & BIOTECH also supply with active principles, trans-
tion enables us to access innovative research and cutting edge dis-
formation and refining of molecules and own developments to
covery with substantial added value and immediate application to
pharmaceutical industry including some of the "top ten" Pharma
the developments under a relatively optimized costs. ND Pharma
Corporations, with presence all around the world.
& Biotech maintains exclusive tights to all the intellectual property assets generated under such cooperation agreement and the re-
search and development conducted. Our market strategy, specially referred to pharmaceutical and the-
ND PHARMA & BIOTECH operations are conducted worldwide.
rapeutic industry is to license our assets to leading international
Since our PHARMA-BUSINESS DIVISION operates directly from
corporations and/or other industry operators (nutrition, food, feed,
our UK Headquarters, other related operational areas as FOOD
etc.) that are interested in further development and commercializa-
and NUTRITION, conduct operations directly from different geogra-
tion of some molecules and/or drugs.
phical areas. 30
ND Pharma & Biotech
No Boundaries At the beginning of 2013, we find ourselves with great opportunity and a clear mission. Our opportunity is based on a foundation driven by and rooted in great science, our focus on developments, products and treatments that are enabling a better quality of life for people. this is why our most speech motto is “Making Life Better” so this is a patients challenge that we assume over some of the most diﬃcult-to-solve problems within the diﬀerent sectors we operate, but mainly within the medial and health sector, where we are making considerably eﬀorts and investments to become a real helping company and a global organization fully aligned around our mission to clearly pursue opportunities within focused advancement and therapeutic areas. We pursue scientific discoveries through our internal programs and through collaboration with other research institutions and academia. Our rigorous scientific orientation – combined with the emphasis we place on being good partners–helps us attract collaborators interested in advancing the most promising compounds and products. For example during past year we built on an existing marketing partnership and obtained exclusive rights from diﬀerent inventors to develop and commercialize novel products made from integrated molecules that we´ve developed in combination with such partners. Some of that compounds are currently undergoing Phase II-III towards clinical testing as both a stand-alone medication and a component of an investigational single-tablet regimen of dosage
for certain medical conditions. Due to this collaborative
company were valued for its contributions to society while
approaches, today we have more promising compounds in our
generates sustainable returns for those who have invested
research and development pipeline than ever before in our
resources in us.
Regardless of what comes our way, our fundamental business
We are an organization that is wholly committed to attracting the
belief remains unchanged: If we invest smartly in research and
best talent possible and the best leaders available, while
development, in innovation and future till the point we
eﬀectively responding to evolving regulatory and economic
revolutionize it, we will be proud of oﬀering true benefit to people,
realities so we can work to deliver treatments to patients around
industries, medicine, health, families and patients everywhere and
the world in the most eﬃcient way possible.
market them thoughtfully, we will do well ... and so will you, as a friend, provider, supplier, employee, executive, agent, distributor
ND Pharma & biotech is constructing on a year basis of great
or whatever role and reason that may get to you close to us.
revenue growth and profitability, while advancing our late-stage pipeline and investing in upcoming product launches. We have kept our promises. We are launching revolutionary products almost within all the important areas and sector of businesses we operate. But we know we have a lot of work to do to meet the opportunity that stands before us. With the foundation we have built, we are well-prepared for the leadership challenges ahead: attend to today’s business while preparing for tomorrow, and pursue a vision where ND Pharma & Biotech invests enthusiastically to prolong and improve lives, to make it better, and we would want to reach the point that our 33
AR13 Writing World
GENERAL INFORMATION AND ENQUIRIES
ND Pharma & Biotech International HQ High Trees Manor House (Mansion),
ND Pharma & Biotech (ALBA-TCP Countries) Oﬃce
Surrey, England, UK
ND Pharma & Biotech Europe
ND Pharma & Biotech Production
PARTICULAR AND/OR SPECIFIC SALES
Surrey, England, UK
CONDITIONS, COMMERCIAL CONTACT AND APPOINTMENTS,
ND Pharma & Biotech Reference
PRODUCT AVAILABILITY AND SERVING
CAPACITY, PLEASE SEND AN E-MAIL TO:
EMEA (Europe, Middle East & Africa) firstname.lastname@example.org
Dorset, UK Labs & Research Centres Maidstone, Kent, UK ND Pharma & Biotech Production
Plant (Europe) Starters/API ́ s
The Netherlands, EU
ND Pharma & Biotech America
New York, New York, USA
ND Pharma & Biotech Latin America
(Central Oﬃce) Panama City, Panama
Plant (USA) Pharmaceuticals Chicago, Illinois, USA ND Pharma & Biotech Reference Center (USA) OLT- Denver, Colorado, USA ND Pharma & Biotech, Southern Europe Logistics Valencia, Spain, EU Tarragona, Spain, EU ND Pharma & Biotech international Commerce & Export Siero, Spain, EU ND Pharma & Biotech, Southern Europe Oviedo, Spain, EU xxxv
Due to security reasons, all enquiries should be made in writing to the above mentioned e-mail
addresses. When commercial and personal contact will be needed an oďŹƒcial or the appropriate person
ND Pharma & Biotech Registered Accountants and Financials A.G. Chartered Accountants
will contact you and your organization. The company reserves the right to refuse any contact
and/or enquiry even without attendance or response. Protection of our IP is the main goal for
us, so every issue, even primary contact should be documented and passed thru our pool of e-mail
GCF Financial Services
and the intelligence unit search of the information source about the enquirer. Every action and information exchange within the company is
The Glaice Water Co. Denver, Colorado, USA Barcelona, Spain (Commercial)
CORPORATE BANKING On rolling appointment to the IPO.
Shortlisted (Nomura and Peel Hunt)
subjected to research prior to follow up contacting and any commercial, trade and/or other nature relationship will be established. If you have any concern regarding this policy please write to: email@example.com
ND Innovation Managerial Services London, UK
Important information about The Company
information, or any other considered within the
established and other in constant expansion and
private sphere of company operations.
ND PHARMA & BIOTECH is a Private Company
Notwithstanding, this information is intended to
Limited by Shares. The Company directors
oﬀer transparent image and in compliance with
esteemed the public launch of the company (IPO)
good company practices manuals for public
within the AIM of the London Stock Exchange,
consistent with previsions to the mid-year of 2014. In the meanwhile The Company and company
DESCRIPTION OF THE BUSINESS
directors, are making every possible eﬀort to accomplish with existing regulations and maximun
Principal activity of the company in the research,
transparence to oﬀer the interested or potential
development and innovation, within every area of
investors every possibility of taking contact with the
s c i e n c e a n d t e c h n o l o g y, e s p e c i a l l y
company, it´s values and objectives, mission, vision
and proceedings, market areas and sectors,
agribusiness and other related, including but not
products, etc. to let them to get formed a complete
limited to this areas, with divisional societies and
frame prior to IPO and/or any other purposed
subsidiaries in some other fields of innovation and
public market initiative.
research, from water technologies to the manufacturing of consumer products, licensing of
Despite this it must be clear that company shares
patents, brands, industrial secrets, utility models
are not on sale, unless private funding interest from
and any other form of proprietary IP.
CURRENT CONSTITUTIONAL DOCUMENTS Memorandum and Articles of Association Bribery Act - Anti Bribery Policy Share Certificates
INSTITUTIONAL AND INVESTOR´S RELATIONS Ms. Mary S. Kay Chief Financial Oﬃcer firstname.lastname@example.org
certain investors that are part of the shareholders from the very beginning and true company
COUNTRY OF INCORPORATION AND MAIN
incorporation. Other investment options exists for
COUNTRY OF OPERATIONS
company divisional societies and subsidiaries, that may be considered and/or treated on a case by case bais. No total or partial information contained within this website and/or other company websites and informational or corporate leaflets, flyers or webpages should be taken as invitation to treat or buy oﬀer of shares, stocks and/or any other form of participation within the company capital, neither a pre-oﬀer facing a future initial public oﬀering (IPO). The company reserves every right over the shares,
ND PHARMA & BIOTECH LTD., is incorporated in England & Wales with Registration Number 8273797 wich is also the main country of operations for administrative and social purposes. The company develop active industrial and commercial promotion and activity in several regios characterized by geographical areas, Europe, Africa and Mid-East Countries (EMEA), Asia, and The Americas, with representatives in these areas xxxvii
ND Pharma & Biotech
Network OFFICIAL DISTRIBUTORS (EXCLUDING AGENTS)
OFFICIAL DISTRIBUTORS Our distributors are specialized companies with an important background within the industry and a sharing interest by our products, services, mission and vision values. Each one of our distributors and partners are
carefully selected, evaluated throughout a strict process and fulfilling higher standards of excellence and
professionalism in the field. All them are composed b a number of individuals and teams with solid backgrounds
and a load of experience. As quality and service is important to us, our oﬃcial agents should comply with such
high standards of delivery. IMPORTANT NOTE ABOUT ACQUIRING THE CONDITION ND Pharma & Biotech and its subsidiaries are constantly considering candidates for representation, agency,
distribution and market sales, so if you´re interested, please send formal oﬀer and/or expression of interest
including a cover letter and a brief company/personal description and documents, to apply for. An Oﬃcial from our
B.I.U. (Business Intelligence Unit) will contact you shortly to define, details and requirements to move forward with
NATURA SELECTION CENTRAL AMERICA
IMPORTADORA D4 ALBA COUNTRIES
your candidacy. Please note that this statement is not an oﬀer or an invitation to treat, neither it constitutes an invitation to submission. ND Pharma & Biotech will treat any information and/or materials received with maximum discretion and care. Notwithstanding do not wait an answer and do not expect any move towards consideration before serious contact and evaluation became performed and a formal notification and/or contracting will made. A number of companies from diﬀerent countries and territories have applied for representation. Evaluations and
ND PHARMA & BIOTECH S.L.
scrutiny is up and running. Please note that there are retail and distributors that are not included within this site as
they are in dependence of existing oﬃcial agencies that maintain operations within diﬀerent countries and
TESLA E.M. (POLAND)
Board of Directors David M. Hwang, President of The Board (Interim oﬃcio) Joseph P. Harford, PhD Chairman and Chief Executive Oﬃcer, ND Pharma & Biotech
Jose M. Lopez Research and Development and Chief Scientific Oﬃcer Jesus Arago, Executive Chief of
Administrative Oﬃces 210 Regent Street, London, England, (On Relocation)
Mary S. Kay, International Chief Financial
The annual meeting of stockholders will
be held at 10:00 a.m. on Thursday, May
Vice Chairman and General Manager
Eusebio Q. Campa, Independent
Lounge & Great Ballroom, London, UK.
Board of Directors
Registered Public Accountant.
Donald Paulsen, Shareholders
Belen Vazquez, Head Legal Counsel and
Secretary of The Board.
Mike V. Vidal, Secretary of The Board of
Corporate Registered Addres
Directors. Senior Leadership Team Joseph P. Harford, MD, PhD Chairman and Chief Executive Oﬃcer, ND Pharma & Biotech Mike V. Vidal, General Manager and
12, 2014 at 1, King Street, Oﬃce´s
ND Pharma & Biotech Co. Ltd. 11, Church Road, Great Bookham, Surrey, United Kingdom Mrs. Maureen Caveley, General Secretary
Rosa Gonzalez Legal Representative and
High Trees Manor House, Surrey,
P.A. to the General Manager.
Equal Opportunity Employer ND Pharma & Biotech and its subsidiaries are proud to be an equal opportunity employer and extends employment to men and women from culturally diverse backgrounds. Our environment respects individual diﬀerences and recognizes each employee as an integral member of our company. Our workforce reflects these values and celebrates the individuals who make up our growing team. xl
Copyright 2013 ND Pharma & Biotech Co. All rights reserved. ND Pharma & biotech Publishing Service. Great Portland Street, London, UK.